"What" Series

What are the requirements for the fragment length in the shRNA design process?

23 April 2024
2 min read

In the design process of shRNA (short hairpin RNA), the fragment length is an important consideration factor, as it can affect the efficiency and specificity of RNA interference (RNAi). Here are some key points regarding the requirements for shRNA fragment length:

· Ideal length: In traditional shRNA design, a 21-nucleotide fragment is typically chosen as the target region because early studies considered that shRNAs of this length are most similar in structure to endogenous microRNAs (miRNAs) and exhibit better gene silencing effects.

· Length variation: Although 21 nucleotides is a common choice, researchers have also explored different lengths of shRNAs, such as 27 bp and 29 bp shRNAs, to evaluate their silencing effects.

· Stem length: The design of shRNA not only includes the target sequence but also the stem length. Studies have found that the stem length of shRNA also affects the gene silencing effect, with 29 bp shRNAs showing stronger silencing effects than 21 bp and 27 bp shRNAs in some cases.

· Avoiding excessively long fragments: If siRNAs (small interfering RNAs) exceed 30 nucleotides, they may trigger an interferon (IFN) response and activate the RNA-dependent protein kinase (PKR) pathway, leading to inhibition of cell proliferation or even apoptosis.

· Design software and tools: Various online tools and software are available for shRNA design, which can help researchers select the optimal length and target sequences while avoiding potential off-target and non-specific targeting effects.

· Experimental validation: After design, the silencing effect of the selected shRNA sequences needs to be experimentally validated, including measuring the expression levels of the target gene by methods such as quantitative fluorescent PCR.

· Vector construction: Once the shRNA sequence is designed, it needs to be cloned into an appropriate expression vector and verified through restriction enzyme sites and linker sequences.

In summary, the requirements for fragment length in the shRNA design process are multifaceted, considering the efficiency and specificity of RNAi as well as potential non-specific effects. By utilizing professional design tools and following design guidelines, researchers can efficiently design shRNAs tailored to their research purposes.

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

NMPA Approves HLX53 Anti-TIGIT Trial with HANSIZHUANG/HANBEITAI for Advanced Liver Cancer
Latest Hotspot
3 min read
NMPA Approves HLX53 Anti-TIGIT Trial with HANSIZHUANG/HANBEITAI for Advanced Liver Cancer
23 April 2024
NMPA Greenlights IND Submission for Initial Clinical Trial Using HLX53 Anti-TIGIT Fc Fusion Protein in Conjunction with HANSIZHUANG and HANBEITAI for Early Treatment in Patients with Advanced or Metastatic Liver Cancer.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 23
Pharma Frontiers
10 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 23
23 April 2024
April 23rd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Vertex Reveals Progress in Suzetrigine (VX-548) for Acute and Neuropathic Pain Treatment
Latest Hotspot
3 min read
Vertex Reveals Progress in Suzetrigine (VX-548) for Acute and Neuropathic Pain Treatment
23 April 2024
Vertex Pharmaceuticals reports advancements in its suzetrigine pain treatment program. Suzetrigine, also known as VX-548, is an oral NaV1.8 inhibitor that could be the first new painkiller class for acute and neuropathic pain in two decades.
Read →
Summary of ADC Drug Development Trends! Revenue to Exceed 26 Billion US Dollars
Graphic Pharma
11 min read
Summary of ADC Drug Development Trends! Revenue to Exceed 26 Billion US Dollars
22 April 2024
In the field of tumor treatment, antibody-drug conjugates (ADCs) have the potential to enhance the efficacy and specificity of cancer therapy by combining monoclonal antibodies with potent cytotoxic drugs.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.